Causes of syncope in patients with Alzheimer's disease treated with donepezil

Drugs and Aging

Volumn 22, Issue 8, 2005, Pages 687-694

  Bordier, Philippe ^a   Lanusse, Stephane ^a   Garrigue, Stephane ^a   Reynard, Charlotte ^a   Robert, Frederic ^a   Gencel, Laurent ^a   Lafitte, Alexia ^a  

^a HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN TUMOR; CAROTID SINUS SYNDROME; CLINICAL ARTICLE; COMPLETE HEART BLOCK; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MALE; ORTHOSTATIC HYPOTENSION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SINUS NODE DYSFUNCTION; SYNCOPE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; FEMALE; HUMANS; INDANS; MALE; PIPERIDINES; SYNCOPE;

EID: 23744467764     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200522080-00005     Document Type: Article

References (41)

1. Fox PJ, Kohatsu N, Max W, et al. Estimating the costs of caring for people with Alzheimer disease in California: 2000-2040. J Public Health Policy 2001; 22: 88-97
2. Fratiglioni L, Launer LJ, Andersen K, et al. Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54: S10-5
3. Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54: S4-9
4. Wolfson C, Wolfson DB, Asgharian M, et al. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med 2001; 344: 1111-6
5. Grutzendler J, Morris JC. Cholinesterase inhibitors for Alzheimer's disease. Drugs 2001; 61: 41-52
6. Shintani EY, Uchida KM. Donepezil: an anticholinesterase inhibitor for Alzheimer's disease. Am J Health Syst Pharm 1997;54: 2805-10
7. Calvo-Romero JM, Ramos-Salado JL. Symptomatic sinus bradycardia associated with donepezil [in Spanish]. Rev Neurol 1999; 28: 1070-2
8. Shepherd G, Klein-Schwartz W, Edwards R. Donepezil overdose: a tenfold dosing error. Ann Pharmacother 1999; 33: 812-5
9. Morganroth J, Graham S, Hartman R, et al. Electrocardiographic effects of rivastigmine. J Clin Pharmacol 2002; 42: 558-68
10. Mant T, Troetel WM, Imbimbo BP. Maximum tolerated dose and pharmacodynamics of eptastigmine in elderly healthy volunteers. J Clin Pharmacol 1998; 38: 610-7
11. Greenberg SM, Tennis MK, Brown LB, et al. Donepezil therapy in clinical practice: a randomized crossover study. Arch Neurol 2000; 57: 94-9
12. Bordier P, Garrigue S, Barold SS, et al. Significance of syncope in patients with Alzheimer's disease treated with cholinesterase inhibitors. Europace 2003; 5: 429-31
13. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th rev. ed. Washington, DC: American Psychiatric Association, 1994
14. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34: 939-44
15. Kapoor WN. Current evaluation and management of syncope. Circulation 2002; 106: 1606-9
16. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. Neurology 1996;46: 1470
17. Atkins D, Hanusa B, Sefcik T, et al. Syncope and orthostatic hypotension. Am J Med 1991; 91: 179-85
18. Bass EB, Curtiss EI, Arena VC, et al. The duration of Holter monitoring in patients with syncope. Is 24 hours enough? Arch Intern Med 1990; 150: 1073-8
19. Brignole M, Alboni P, Benditt DG, et al. Guidelines on management (diagnosis and treatment) of syncope: update 2004. Eur Heart J 2004; 6: 467-537
20. Almquist A, Gornick CC, Benson Jr DW, et al. Carotid sinus hypersensitivity: evaluation of the vasodepressor component. Circulation 1985; 71: 927-36
21. Kenny RA, Richardson DA, Steen N, et al. Carotid sinus syndrome: a modifiable risk factor for nonaccidental falls in older adults (SAFE PACE). J Am Coll Cardiol 2001; 38: 1491-6
22. Pavri BB, Ho RT. Syncope: identifying cardiac causes in older patients. Geriatrics 2003; 58: 26-31
23. Rees SA, Curtis MJ. Tacrine inhibits ventricular fibrillation induced by ischaemia and reperfusion and widens QT interval in rat. Cardiovasc Res 1993; 27: 453-8
24. Savci V, Gurun MS, Cavun S, et al. Cardiovascular effects of centrally injected tetrahydroaminoacridine in conscious normotensive rats. Eur J Pharmacol 1998; 346: 35-41
25. Fitzpatrick AP, Lee RJ, Epstein LM, et al. Effect of patient characteristics on the yield of prolonged baseline head-up tilt testing and the additional yield of drug provocation. Heart 1996; 76: 406-11
26. McLaren AT, Allen J, Murray A, et al. Cardiovascular effects of donepezil in patients with dementia. Dement Geriatr Cogn Disord 2003; 15: 183-8
27. Click RL, Gersh BJ, Sugrue DD, et al. Role of invasive electrophysiologic testing in patients with symptomatic bundle branch block. Am J Cardiol 1987; 59: 817-23
28. Graham LA, Gray JC, Kenny RA. Comparison of provocative tests for unexplained syncope: isoprenaline and glyceryl trinitrate for diagnosing vasovagal syncope. Eur Heart J 2001; 22:497-503
29. Del Rosso A, Ungar A, Bartoli P, et al. Usefulness and safety of shortened head-up tilt testing potentiated with sublingual glyceryl trinitrate in older patients with recurrent unexplained syncope. J Am Geriatr Soc 2002; 50: 1324-8
30. Kumar NP, Youde JH, Ruse C, et al. Responses to the prolonged head-up tilt followed by sublingual nitrate provocation in asymptomatic older adults. Age Ageing 2000; 29: 419-24
31. Kapoor W, Snustad D, Peterson J, et al. Syncope in the elderly. Am J Med 1986; 80: 419-28
32. Lipsitz LA, Wei JY, Rowe JW. Syncope in an elderly, institutionalised population: prevalence, incidence, and associated risk. Q J Med 1985; 55: 45-54
33. Kenny RA. Syncope in the elderly: diagnosis, evaluation, and treatment. J Cardiovasc Electrophysiol 2003; 14: S74-7
34. Soteriades ES, Evans JC, Larson MG, et al. Incidence and prognosis of syncope. N Engl J Med 2002; 347: 878-85
35. O'Shea D. Setting up a falls and syncope service for the elderly. Clin Geriatr Med 2002; 18: 269-78
36. Rubenstein LZ, Josephson KR. The epidemiology of falls and syncope. Clin Geriatr Med 2002; 18: 141-58
37. Kapoor WN, Karpf M, Wieand S, et al. A prospective evaluation and follow-up of patients with syncope. N Engl J Med 1983; 309: 197-204
38. Hu T, Huang L, Cartwright WS. Evaluation of the costs of caring for the senile demented elderly: a pilot study. Gerontologist 1986; 26: 158-63
39. Rice DP, Fox PJ, Max W, et al. The economic burden of Alzheimer's disease care. Health Aff 1993; 12: 164-76
40. Johnson N, Davis T, Bosanquet N. The epidemic of Alzheimer disease: how can we manage the costs? Pharmacoeconomics 2000; 18: 215-23
41. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998; 88: 1337-42